Vincerx Pharma Inc. (VINC)
NASDAQ: VINC
· Real-Time Price · USD
0.05
-0.00 (-1.96%)
At close: Jun 09, 2025, 12:40 PM
-1.96% (1D)
| Bid | 0.05 |
| Market Cap | 264.33K |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -22.64M |
| EPS (ttm) | -5.79 |
| PE Ratio (ttm) | -0.01 |
| Forward PE | -0.01 |
| Analyst | Buy |
| Ask | 0.05 |
| Volume | 95,500 |
| Avg. Volume (20D) | 825,142 |
| Open | 0.05 |
| Previous Close | 0.05 |
| Day's Range | 0.05 - 0.06 |
| 52-Week Range | 0.04 - 17.18 |
| Beta | 1.48 |
About VINC
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol VINC
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for VINC stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock Forecasts2 months ago
-49.24%
Vincerx Pharma shares are trading lower after the ...
Unlock content with
Pro Subscription
4 months ago
-5.45%
Vincerx Pharma shares are trading higher after the company and Oqory announced Phase 1a/1b results for Anti-TROP2 ADC OQY-3258 in solid tumors. Additionally, there is a proposed merger between the two companies to advance Phase 2 trials and build an ADC pipeline.
